Authors
Hartej Gill, Sebastian Badulescu, Hiya Shah, Ryan M Brudner, Joshua D Di Vincenzo, Aniqa Tabassum, Lee Phan, Kayla M Teopiz, Cristian-Daniel Llach López, Joshua D Rosenblat, Roger S McIntyre, Rodrigo B Mansur
Published in
Journal of affective disorders. Pages 122714. Nov 08, 2026. Epub Nov 08, 2026.
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) improve effort-based decision-making in major depressive disorder (MDD), but whether this reflects their metabolic effects is unknown. We examined whether this effect is statistically mediated by metabolic change.
Exploratory, post-hoc secondary analysis of a 16-week, double-blind, placebo-controlled trial (NCT04466345) of adjunctive oral semaglutide versus placebo in 72 adults with MDD and overweight/obesity. The Effort-Expenditure for Rewards Task yielded an effort-discounting parameter (k) via a subjective-value model. Mediation by change in body mass index, percent body fat, glycated hemoglobin, and insulin resistance (HOMA-IR) was tested using bootstrapped mediation models (n = 46-53) and generalized estimating equations (GEE; n = 33-36), with depressive-symptom and cognition change as competing mediators. No adjustment was made for multiple comparisons.
Semaglutide significantly reduced effort discounting (GEE treatment × visit β = -1.78; 95% CI, -3.34 to -0.23; P = .025). Modeling metabolic change did not attenuate this effect; the total indirect effect was opposite in sign to the direct effect (+2.04; direct, -2.93), a suppression pattern that did not survive exclusion of high-influence observations. Depressive-symptom and cognitive change did not account for the effect; reverse models showed no mediation of metabolic improvement by Δk.
Semaglutide's effect on effort-based decision-making in MDD was not statistically mediated by the metabolic variables assessed, nor by change in depressive symptoms or cognition. These exploratory findings are consistent with a weight-independent effect but do not establish a central mechanism. Limitations include the post-hoc design, small effective sample, unadjusted comparisons, and functional unblinding.
PMID:
43000069
Bibliographic data and abstract were imported from PubMed on 09 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 15
- Comments 0